Join our daily newsletter At The Bell to receive exclusive market insights
- Zelira Therapeutics (ZLD) receives ethics approval for its Phase 2a clinical trial for chronic pain
- As part of its licensing and project management with Levin Health, the study will evaluate the efficacy of Zelira’s cannabinoid formulation for treating sports-related chronic pain
- With approval now granted from the Bellberry Human Research Ethics Committee, the study is expected to begin in April 2022, and will aim to enrol 114 patients
- Zelira Therapeutics is trading sideways on the market this morning, sitting at 3.4 cents
Zelira Therapeutics (ZLD) has received ethics approval for its Phase 2a clinical trial for chronic pain.
As part of its licensing and project management with Levin Health, the Phase 2a study will evaluate the efficacy of Zelira’s cannabinoid formulation, ZTL-106, for treating sports-related chronic pain experienced by retired professionals and amateur athletes.
Undertaken in collaboration with La Trobe University’s Sport and Exercise Medicine Research Centre, the randomised, double-blind, placebo-controlled clinical trial will investigate the use of ZTL-106 as an effective medicinal cannabis drug in treating people with chronic pain, specifically following musculoskeletal injury.
Sports medicine expert Professor Peter Brukner is the Principal Investigator for the trial.
Under the terms of the agreement, Levin will provide the funding for the trial, while Zelira will be contracted to project manage.
Zelira Therapeutics Managing Director, Oludare Odumosu, said Zelira is excited to have partnered with Levin Health in this innovative drug development project.
“We are thrilled that our world class formulation and expertise in fast tracking drug developments has been born out with the Bellberry ethics approval for this phase 2 clinical trial,” Dr Odumosu said.
“We look forward to continuing our partnership with Levin Health to validate a proprietary product that will help treat chronic pain.”
With approval now granted from the Bellberry Human Research Ethics Committee, the study is expected to begin in April 2022, and will aim to enrol 114 patients.
Zelira Therapeutics is trading sideways on the market this morning, sitting at 3.4 cents.
